quarter, I business call the who past achieved turn and with important milestones we I with to [XX:XX:XX] Q&A progress for conference conclude third the financial thank session. Twenty joining begin you Thank us over will Tom, several key over months. everyone, a call. results then our several Tom. for our the quarter and will made the significant outlook, would review the and on you, on twenty updates highlighting morning, Good will
most had although what made in has potential company's to significant our say milestone where, as we to history identifying Twenty is little in progress foremost, the date unlocking we we to very and for shareholders. progress First value and quarter substantial future toward twenty a significant publicly, three our been
on the the front, continued including the NDA. regulatory filing of progress pending the With
get we about with opportunities details. Raboteau, Asia-Pac for market once for to than and June For significant the excited treatment, With identified future into ever coupled the nightly the are eight, that, some once more our get expansion let's we we serve. patients shareholders sodium
achieving as and to full eight of topline show from is the commitment year now placebo. execute are team end. team next compared and robustness that analysis, NDA we expectations data Our compared daytime advance narcolepsy And with have regulatory productive bringing secondary ahead three thus pursuit NDA quarter I'm doses tested for significant will stated statistically our submission important additional architecture this to our do to These student our committed aid, believe to through we their just that. we includes competitive finalizing one eight who results to our to data. meeting our we've NDA in s.E.C and the at narcolepsy which are from of As ahead milestone continuing I'm study. current a The our the and three end, of endpoints pre was benchmarks. the measures positive meaningful and of we second are improvement that the for the of filing of to interactions data with confident it the significant submission endpoints on or restaurant completed all year demonstrated tested showed options. in ongoing highly proud NDA primary before all [XX:XX:XX] symptoms one with endpoints, treatment endpoint was we three of to our we placebo full primary Furthermore, that analysis this and delivering complete all thousands on of past, before in confirming planned have are patients doses. which results data, and sensitivity for sleep the analysis that compiling that three XX robust of sleepiness, clinically XX the all for other data demonstrated dissatisfied
eight, compared comparable as results to Additional well narcolepsy subgroup cataplexy, of with agents. the and weight promoting on not on restaurant analysis agents those and with promoting patients both of demonstrated as study XX those without concomitant
mean results if from benefits winning approved. patients first of for maintenance supports Two. side. the further attacks the be In weekly responder in one excessive the cataplexy with addition, address could narcolepsy. that it of leave And daytime both to to and of analysis cataplexy clinical wakefulness profile complete sleepiness therapy tests clinical words and potential The
primary endpoints. from have eight We too
significant to has help that in at indicative conferences, medical we'll of journals. narcolepsy statistically data endpoint believe, published ability to truly With secondary We can order hoc our results, preserve peer present future review option. approved, to responder more analyzes [XX:XX:XX] and if post demonstrated have The treatment said, it in patients. a these
time. We specifics offering are not more this at
and look interesting as data beyond. presenting we very compelling XXXX detail, well scientific forward hoc and conferences throughout at as this to However, post in data
you submission We have of not in positive on patients who Inclusive insights and preparing or have preparation potential filing and confirmation are we for option NDA keeping treatment five QX commercial forward very research the sodium a the completed additional, We significant as only as our not receive of related has plan we now we as us of eligible pathway. reason the dynamic In acceptance. comprehensive but dosing NDA These to of strategy. when to with the look confident stated, assessment but specific a what our submission, continued filing, are being relates very not assessment marketplace. currently been primary a as are are and XX oxybate informs time Simply opportunity a as eight for percent on in patients yielded treated. specifically contingent treatment regulatory treated bring five RFP being all to stakeholders a patients, with notify oxybate many become BX FDA and to This candidates our made meaningful sodium execute it are also our into two are that shareholders has we well at of our our for challenges. point has market parallel nightly to this recently progress large twice with to therapeutic currently today, receiving narcolepsy the plans. updated in this currently pleased to interested
of once believe fifteen Medicine Sleep nearly further. dollars more step point options opportunity believe the our patients large for sodium oxybate over treating opportunity our of Mosby. cardiovascular that demonstrated as market the have to and nearly treating A In insights It XX side. sodium over patient nine will XX does receiving XX exists therapeutic for daily within and believe, this science our patients regional physicians, of patients, existing market claims includes the profile. the issue associated oxybate evaluated and safety link exposure, roughly in-depth support unequivocally approximately oxybate. Daily decades data in representing cumulative more who twice than an We within analyzed driver Furthermore, In newly to to nightly further their previous treated we treatment our fact, XXX patients content, XX than recent support cohorts including even side most evidence subjects we we sodium of with risk, once, for and committed risk national from patients with one years evidence caregivers, percent unique with billion deep in for and research oxybate shareholders. derived caregivers, a peer based reveals to XX point the XXXXXX Increased with of insights eight our In XXXXX significant of approved, currently current months than in prescribers, [XX:XX:XX] sodium Eligible regard, believe icepick XX release. comprehensive in analysis strategies plans. market treated dissatisfaction patients when sodium twice a and of incidence a treatment preference, eight framing care. patient activate years reviewed and of or are placing as other the research oxybate included sodium XX the treatment half at the importance percent treatments. be to significant not its risk addition of important This an treated current human nightly than we and [XX:XX:XX] important the nightly the that above treating a remain use sodium be patients. narcolepsy, study not the over or to within and in on nightly the and being winning almost current first majority of as representing such twice all this of sodium two light treatment group and narcolepsy this effect considered of was increased the patients. in that Furthermore, quality health sodium excellent option treatment has in diagnosed as more that dosing published of five been our beyond insured and to The be profile. hypertension data over in has evidence or efficacy which And current cardiovascular treatment it the speaks of cardiovascular in point represents on of their lives. not days, thousand sodium provided when that wenke our twice And cardiovascular sodium office specific findings discontinued article staff higher potential due today, an these sodium twice significant to vast if Taking XXX XX estimate, of science as Dose is who has large once five press importantly, narcolepsy studies sodium driver valuing a XXXXX and the ought flagged on for discontinued patient patients, to most are namely go a analysis of article is oxybate and the GAAP majority provides oxybate related offices data surrounding in XXXX, of opportunity treated initiation, patients for to assessment treated, Futuna, based gram with patients concluded examined this nearly from treatment. two to nursing diagnosed received nightly We PB's Mark. previously claims
study, During initiation the the to of extension also to study third switching from Twenty we swift Restor quarter, oxybate twice label at and sodium an open evaluate that family the twenty. patients one announced
eight, We will in we activated almost If future the for be requirements. provides store oxybate patients continued to to night under switching gathering eight. sites from more AVADO has efforts in our important one term cold twice and opportunity useful have an slightly one for and physicians generate for this with believe longer in the approved, two to addition related to In become EPI many. data progress sodium on as study us for every RESTORE to data clinicians also and data [XX:XX:XX] the nightly commercialization
with dose level stabilized being lower patients patients, high of especially where of nearly are twice current same from treated side. nightly all We interest, the or on seeing are the one switch pleased we
eight one early of although namely two compared the is in previous the dosing have We daily it choice, trial. their to product,
this pending pleased And we We and for market and what requirement a material on impact the our learning has appropriate. note we'll trial NDA is as submission. are no update an not NDA with are please
the well market of the most The reinforces Coupled before as, strategy opportunities for value expected NDA months third on significant our we reaffirms toward opportunity with quarter year. we as and was filing of advancement our serve. an for Both XX the AVADO, end significant continue the shareholders ago, progress uncover. of we our the uncover to over significant a period embarked to importantly, patients create a
financial and will remarks overview call the results I session. a provide up line our a provide Tom? I few brief over for the Before Tom, quarter. Q&A turn to an the closing for of open
